Skip navigation

Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis

Published: 16/09/2016 / Number of Pages: 98 / Price: £745.00

Order Now

A PDF is included in report price, all other options also include a PDF file. For further details on purchase options, please click here.

A single user licence is included in report price, but we offer a range of licences to suit your needs. For further details, please click here.

Total Price: £745.00

Order/Delivery FAQ

Other Questions?

Call us on
01242 235724
Or email us

Download Brochure

Introduction and Overview

The 3rd edition of the report 'Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis' addresses the scale of construction activity in the pharmaceutical and biotechnology industry alongside the key contractors operating in that sector. It also assesses the health of the pharmaceutical industry and whether prospective industry performance is likely to lead to greater levels of capital and construction investment.

Key sections covered:

  • Market size and overview - value, market drivers and key issues, R&D and manufacturing activity.
  • Construction activity - in the pharmaceutical and biotechnology industries.
  • Main manufacturing and R&D facilities - the key centres of the South East, East of England, North West, North East and Scotland.
  • Construction capability - major companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects.
  • Funding and investment - analysis of Government resource and capital funding for science and research.

Key areas of insight include:

  • Analysis of the impact of Brexit on the UK pharmaceutical sector - there are significant issues for the industry including the regulation of medicines, EU clinical trials regulation, EU funding for research, access to R&D facilities, the single market, skills base.
  • Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance.
  • Construction costs and issues in the design of pharmaceutical R&D and manufacturing facilities including legislation, regulatory requirements, containment and environmental issues, cleanroom and laboratory design.
  • Detailed analysis of pharmaceutical clusters and centres of excellence in the UK. Many of the UK's biotech firms are located in an area known as 'The Golden Triangle', with the centres of London, Cambridge, Oxford and Stevenage housing the UK's largest biomedical cluster in the UK.
  • Review of the main challenges facing the pharmaceutical sector including slowing R&D pipelines, dwindling healthcare budgets, rising costs, impending 'patent cliffs', increased regulatory controls, the influence of the generic drugs market and increased pricing pressures.

Some of the companies mentioned in the report include:

ABB Group, AECOM, AMEC Foster Wheeler, Ardmac, Bassaire, BDP, Bilfinger SE, Cavendish Engineers, Clean Air Technologies, Clean Modules, Cleanroom Design & Construction, Cleanroom Solutions, ClearSphere, Enbloc Cleanrooms, ISG, Jacobs Engineering, John Sisk & Sons, Kier Group, Laing O'Rourke, M+W Group, Mach-Aire, Merit Merrell, Morgan Sindall, Nuvia, PM Group, Precision Cleanrooms, SDC, Sheppard Robson, Validair, Wilson Mason.

Market Overview

  • Market definition, size and value, overview of the global pharmaceutical market, overview of the UK pharmaceutical market: biopharmaceuticals; medical technology; digital health; genomics sector.
  • Location of UK biopharmaceutical manufacturing and R&D sites.
  • Pharmaceutical/biotechnology clusters and centres of excellence: Oxfordshire biocluster; London, Cambridge and Stevenage bioclusters.
  • Regional concentration of pharmaceutical manufacturing and R&D: Northwest; East, Southeast and London; Northeast; Scotland.
  • Future of pharmaceutical manufacturing operations in the UK.
  • Value of pharmaceutical industry to the UK economy: UK trade in pharmaceuticals, sales of pharmaceutical drugs to the NHS.
  • Pharmaceutical R&D in the UK: government funding for science R&D (resource & capital funding); pharmaceutical company investment in R&D; R&D pipeline.
  • Market drivers and key issues in the pharmaceutical industry: drug patent expirations; generic drugs market; university collaboration with the pharmaceutical industry; tax implications and government legislation; long-term implications of 'brexit' on the UK pharmaceutical industry.

Construction Activity

  • Construction output in the UK pharmaceutical and biotechnology sector, forecast through to 2020, prospects for development in construction within this end use sector.
  • Construction in the industrial sector, future prospects in construction output within the sector, key influencing factors, growth in factories and warehouses.
  • Capital expenditure in the UK pharmaceutical & biotechnology sectors: R&D capital and manufacturing capital.
  • Pharmaceutical construction/development pipeline - confirmed projects to 2020.
  • Construction issues in the pharmaceutical industry - construction costs; contamination control issues; clean rooms; containment laboratories; legislation/guidelines/standards for cleanroom construction.
  • UK science parks and university innovation campuses.
  • UK Enterprise Zones and Catapult Centres.

Construction Capability

  • Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance.
  • Major engineering construction companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects - capability and project experience.

Leading Pharmaceutical Companies

  • Overview and Pharmaceutical Company League Tables (Global and UK).
  • Pharmaceutical company profiles: Abbvie; AstraZeneca; Boehringer Ingelheim; GSK; Johnson & Johnson; Merck; Novartis; Pfizer; Roche; Sanofi.
  • Other smaller pharmaceutical/biotechnology companies: biotechnology/therapeutics & diagnostics; biotechnology R&D; pharmaceutical.

Report Summary

The UK is one of the largest pharmaceutical markets in the world, and the sector makes a greater contribution to the UK economy than any other industrial sector. Though there has been some scaling-back of R&D budgets in the UK in recent years, due to issues such as slowing R&D pipelines, dwindling R&D and healthcare budgets, rising costs, impending 'patent cliffs', increased regulatory controls and increased pricing pressures, pharmaceutical manufacturing investment activity in the UK has been slowly increasing over the last couple of years. Confidence has begun to return to the market and this looks set to continue into 2016-17, despite the ongoing threat of global economic uncertainty and the more recent threat of the UK's exit from the EU. The level of construction output in the pharmaceutical sector has also grown in recent years, with a focus of developments on high-value laboratories / cleanrooms.

Although the volume of work has increased, tender opportunities are becoming increasingly competitive resulting in tighter margins and, despite renewed activity, many UK pharmaceutical producers are not significantly increasing levels of capex. However, the Government has announced a forward pipeline of over £1.9bn worth of capital projects in the pharmaceutical and biotechnology sectors between now and 2020. In addition to these confirmed capital projects, a number of expansion plans have been announced by leading pharmaceutical companies, which should be of interest to construction companies and their supply chains operating in the pharmaceutical sector. In addition, a major trend in 2016 is the continued capital investment in science parks and university innovation campuses, with a focus on R&D, and enterprise zones.

In terms of construction costs, pharmaceutical R&D and manufacturing facilities are among the most energy intensive and expensive of buildings and are also highly regulated in terms of design and function. Current design and construction trends are moving away from 'bespoke' buildings to flexible and mobile laboratories and cleanrooms requiring less time to design and build and incorporating modern methods of construction. The demand for mobile or modular cleanrooms is increasing driven by industry cutbacks which have forced many pharmaceutical companies to rethink their business and manufacturing operations. Increasing specialisation within the pharmaceutical industry has brought about varied opportunities for construction engineers and contractors to design and develop R&D facilities, pharmaceutical production processes, and assembly of drug delivery devices/systems, construction and maintenance of highly specialised production facilities and associated service/support facilities.

So far, the larger pharmaceuticals companies appear to have been largely unscathed by the UK vote to leave the EU - with a significant proportion of the sales of the major pharmaceutical companies generated overseas and a weaker pound likely to result in a significant rise in profits. However, Brexit has the potential to create significant issues for the UK life sciences industry including the regulation of medicines, EU clinical trials regulations, EU funding for research and access to R&D facilities, access to the single market and R&D workforce and intellectual property. The industry is expected to continue to show modest growth over the next few years, reflecting the positive growth factors from the growing UK pharmaceutical industry, but constrained by the economic uncertainty created by the UK's vote to leave the EU.


List of Report Contents

  1. Contents Listing
  2. 1. INTRODUCTION 6
  3. 1.1 INTRODUCTION 6
  4. 1.2 SOURCES OF INFORMATION 6
  5. 2. SUMMARY AND MARKET PROSPECTS 8
  6. 2.1 SUMMARY 8
  7. 2.2 UK PHARMACEUTICALS SECTOR 10
  8. 3. ECONOMIC ENVIRONMENT 11
  9. 3.1 GDP 11
  10. 3.2 INFLATION & INTEREST RATES 13
  11. 3.3 UNEMPLOYMENT 14
  12. 3.4 HOUSEHOLD CONSUMPTION 14
  13. 3.5 HOUSING & CONSTRUCTION 15
  14. 3.6 STERLING 15
  15. 3.7 POPULATION PROFILE 16
  16. 3.8 CONCLUSIONS 16
  17. 4. CONSTRUCTION ACTIVITY IN THE UK PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS 18
  18. 4.1 CONSTRUCTION INDUSTRY 18
  19. 4.1.1 Overall Construction Industry 18
  20. 4.1.2 Non-Domestic Construction 19
  21. 4.2 DEFINITION - PHARMACEUTICALS AND BIOTECHNOLOGY 22
  22. 4.3 MARKET SIZE 22
  23. 4.3.1 Current Situation 22
  24. 4.3.2 Market Prospects 24
  25. 4.3.3 Construction Pipeline 25
  26. 4.4 CAPITAL EXPENDITURE IN THE PHARMACEUTICAL SECTOR 28
  27. 4.5 SCIENCE PARKS / UNIVERSITY INNOVATION CAMPUSES 29
  28. 4.6 ENTERPRISE ZONES 33
  29. 4.7 CONSTRUCTION ISSUES IN THE PHARMACEUTICAL INDUSTRY 34
  30. 4.7.1 Construction Costs 34
  31. 4.7.2 Contamination Control Issues 35
  32. 5. CONSTRUCTION CAPABILITY AND SUPPLY CHAIN 41
  33. 5.1 OVERVIEW OF THE SUPPLY CHAIN 41
  34. 5.2 CONSTRUCTION CONSULTANTS AND CONTRACTORS 41
  35. 5.3 SPECIALIST CLEANROOM CONSTRUCTION, SUPPLY AND SERVICES 50
  36. 6. PHARMACEUTICAL INDUSTRY MARKET SIZE AND OVERVIEW 54
  37. 6.1 MARKET DEFINITION, SIZE AND VALUE 54
  38. 6.1.1 Global Pharmaceutical Market 54
  39. 6.1.2 UK Pharmaceutical Market 55
  40. 6.1.3 Biopharmaceutical Sector 56
  41. 6.1.4 Medical Technology Sector 57
  42. 6.1.5 Digital Health Sector 57
  43. 6.1.6 Genomics Sector 57
  44. 6.1.7 Location of Biopharmaceutical Manufacturing Sites 58
  45. 6.2 PHARMACEUTICAL / BIOTECHNOLOGY CLUSTERS 61
  46. 6.2.1 Oxfordshire BioCluster 61
  47. 6.2.2 London, Cambridge and Stevenage BioClusters 61
  48. 6.2.3 Regional Concentration of Pharmaceutical Manufacturing/R&D 62
  49. 6.2.4 Future of Pharmaceutical Manufacturing Operations in the UK 66
  50. 6.3 VALUE OF PHARMACEUTICAL INDUSTRY TO THE UK ECONOMY 68
  51. 6.3.1 UK Trade in Pharmaceuticals 68
  52. 6.4 SALES OF PHARMACEUTICAL DRUGS TO THE NHS 69
  53. 6.5 PHARMACEUTICAL R&D IN THE UK 69
  54. 6.5.1 Government Funding for Science R&D 70
  55. 6.5.2 Pharmaceutical Company Investment in R&D 72
  56. 6.5.3 R&D Pipeline 74
  57. 6.6 MARKET DRIVERS AND KEY ISSUES IN THE PHARMACEUTICAL INDUSTRY 76
  58. 6.6.1 Key General Issues Facing the Pharmaceutical Sector 76
  59. 6.6.2 Future of the UK Pharmaceutical Sector 77
  60. 7. LEADING COMPANIES IN THE PHARMACEUTICAL & BIOTECHNOLOGY SECTORS 82
  61. 7.1 OVERVIEW 82
  62. 7.2 PHARMACEUTICAL COMPANY LEAGUE TABLES 82
  63. 7.2.1 Global 82
  64. 7.2.2 UK 84
  65. 7.3 COMPANY PROFILES 84
  66. 7.3.1 AbbVie 84
  67. 7.3.2 AstraZeneca 85
  68. 7.3.3 Boehringer Ingelheim 86
  69. 7.3.4 GSK 87
  70. 7.3.5 Johnson & Johnson 89
  71. 7.3.6 Merck 90
  72. 7.3.7 Novartis 91
  73. 7.3.8 Pfizer 92
  74. 7.3.9 Roche 94
  75. 7.3.10 Sanofi 95
  76. 7.4 OTHER PHARMACEUTICAL/BIOTECHNOLOGY COMPANIES 96
  77. 7.4.1 Biotechnology - Therapeutics/Diagnostics 96
  78. 7.4.2 Biotechnology R&D 97
  79. 7.4.3 Pharmaceutical 98
  1. Tables & Charts
  2. CHART 1 ESTIMATED VALUE OF CONSTRUCTION OUTPUT IN THE PHARMACEUTICALS AND BIOTECH INDUSTRY BY VALUE (£M AT CURRENT PRICES) 2011-2020 8
  3. TABLE 2 GDP DATA - 2013-2016 - KEY CONSTITUENT ELEMENTS 12
  4. CHART 3 INTEREST RATES AND INFLATION (CPI) FROM 2000-2020 13
  5. CHART 4 PDI & SAVINGS RATIO AT CURRENT PRICES 2000-2020 14
  6. TABLE 5 EXCHANGE RATE FLUCTUATIONS 2012-2018 - STERLING TO THE DOLLAR, AND THE EURO, SPOT RATES 16
  7. CHART 6 CONSTRUCTION OUTPUT (GB) NEW WORK AND RMI ANALYSIS 2011 TO 2020 BY VALUE (£ BILLION AT CURRENT PRICES) 18
  8. CHART 7 CONSTRUCTION OUTPUT (GB) NEW WORK AND RMI ANALYSIS 2015 TO 2020 BY VALUE (£ BILLION AT CURRENT PRICES) 18
  9. CHART 8 NON RESIDENTIAL CONSTRUCTION OUTPUT (GREAT BRITAIN) NEW WORK & RMI - CURRENT PRICES (£BN) 2011 -2020 20
  10. CHART 9 NON RESIDENTIAL CONSTRUCTION OUTPUT (GREAT BRITAIN) BY SECTOR CURRENT PRICES (£BN) 2014 -2020 21
  11. CHART 10 ESTIMATED VALUE OF CONSTRUCTION OUTPUT IN THE PHARMACEUTICALS AND BIOTECH INDUSTRY BY VALUE (£M AT CURRENT PRICES) 2011-2020 22
  12. TABLE 11 UK SCIENCE AND RESEARCH PROJECTS - FORWARD CONSTRUCTION PIPELINE 26
  13. CHART 12 UK PHARMACEUTICAL INDUSTRY CAPITAL EXPENDITURE - R&D AND MANUFACTURING OPERATIONS (£M) 2009 - 2014 28
  14. TABLE 13 UK SCIENCE PARKS - SIZE, GEOGRAPHICAL SPREAD, SECTORS AND KEY PARTNERS 30
  15. TABLE 14 AIRBORNE PARTICULATE CLEANLINESS CLASSES FOR CLEANROOMS (BASED ON ISO 14644-1) 37
  16. CHART 15 GLOBAL PHARMACEUTICAL MARKET BY VALUE (£BN) - 2011 - 2020 54
  17. CHART 16 SIZE OF THE UK LIFE SCIENCES SECTOR BY TURNOVER AND NO. COMPANIES 2015 (BIOPHARMACEUTICALS AND MEDICAL TECHNOLOGY) (BY % AND VALUE £BN) 56
  18. TABLE 17 BIOPHARMACEUTICAL / MEDICAL TECHNOLOGY SECTORS - MAJOR COMPANIES AND GEOGRAPHICAL LOCATION OF FACILITIES IN THE UK - MANUFACTURING, R&D, AND PACKAGING & LOGISTICS 59
  19. CHART 18 UK PHARMACEUTICAL SECTOR - DISTRIBUTION OF UK MANUFACTURING AND R&D SITES 62
  20. CHART 19 PHARMACEUTICAL TRADE IN THE UK - 2010- 2015 BY VALUE (£M) 68
  21. TABLE 20 GOVERNMENT RESOURCE FUNDING FOR SCIENCE AND RESEARCH 2016-2020 BY FUNDING PROGRAMME (£M) 70
  22. TABLE 21 GOVERNMENT CAPITAL FUNDING FOR SCIENCE AND RESEARCH 2016-2020 BY FUNDING PROGRAMME (£M) 72
  23. TABLE 22 TOP 25 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY GLOBAL R&D SPEND 2015 (£BN AND BY % OF TURNOVER) 74
  24. TABLE 23 TOP 20 GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY DRUG PIPELINE SIZE IN 2015 AND 2016 75
  25. TABLE 24 TOP 20 GLOBAL PHARMACEUTICAL COMPANIES BY MARKET SHARE (%) 2015 82
  26. TABLE 25 TOP 10 PHARMACEUTICAL COMPANIES MARKET SHARE (%) 2015 84
  27. TABLE 26 ABBVIE - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 85
  28. TABLE 27 ASTRAZENECA - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 86
  29. TABLE 28 BOEHRINGER INGELHEIM - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS 87
  30. TABLE 29 GSK- KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS 88
  31. TABLE 30 JOHNSON & JOHNSON - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 90
  32. TABLE 31 MERCK - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 91
  33. TABLE 32 NOVARTIS - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 92
  34. TABLE 33 PFIZER- KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 94
  35. TABLE 34 ROCHE - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 95
  36. TABLE 35 SANOFI - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 96

The 'Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis' costs £745+VAT (if applicable) for a PDF version.

Other formats are available - click here for a information about available report formats. All AMA reports are sold with a single user licence as standard. For more information about AMA licences click here.